Mutations in the isocitrate dehydrogenase (IDH) family, notably IDH1 and IDH2, have been identified in several cancers such as grade II and III gliomas and acute myeloid leukemia (AML) [6,7,8]. This evidence concerns the gene IDH2 and acute myeloid leukemia.